Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Conference Coverage
Relatlimab Added to Nivolumab Has Robust Anti-Tumor Activity in Advanced Melanoma
11/22/2023

Stephanie Holland 

Stephanie Holland 
Biomarker analyses from patients enrolled in the RELATIVITY-047 trial revealed relatlimab added to nivolumab has robust anti-tumor activity among patients with advanced melanoma with lower CD8+ T cell infiltration.
Biomarker analyses from patients enrolled in the RELATIVITY-047 trial revealed relatlimab added to nivolumab has robust anti-tumor activity among patients with advanced melanoma with lower CD8+ T cell infiltration.
Biomarker analyses from patients...
11/22/2023
Oncology
Quiz
Tisotumab Vedotin for Cervical Cancer
11/21/2023
11/21/2023
Oncology
Juergen C. Becker, MD, PhD
Conference Coverage
Avelumab Plus Cetuximab for Advanced Cutaneous Squamous Cell Carcinoma
11/20/2023

Featuring Juergen C. Becker, MD, PhD

Featuring Juergen C. Becker, MD, PhD ...
Juergen C. Becker, MD, PhD, German Cancer Consortium, discusses preliminary findings from the phase 2 AliCe study combining avelumab with cetuximab for patients with advanced, unresectable cutaneous squamous cell carcinoma.
Juergen C. Becker, MD, PhD, German Cancer Consortium, discusses preliminary findings from the phase 2 AliCe study combining avelumab with cetuximab for patients with advanced, unresectable cutaneous squamous cell carcinoma.
Juergen C. Becker, MD, PhD,...
11/20/2023
Oncology
Arlene Siefker-Radtke, MD, MD Anderson Cancer Center
Videos
Erdafitinib Shows Similar OS to Pembrolizumab Among Patients With FGFR-Altered Advanced/Metastatic Urothelial Carcinoma
11/16/2023

Featuring Arlene Seifker-Radtke, MD

Featuring Arlene Seifker-Radtke, MD ...
Arlene Siefker-Radtke, MD, discusses the THOR trial which found that erdafitinib had a similar OS to pembrolizumab among patients with advanced or metastatic urothelial carcinoma.
Arlene Siefker-Radtke, MD, discusses the THOR trial which found that erdafitinib had a similar OS to pembrolizumab among patients with advanced or metastatic urothelial carcinoma.
Arlene Siefker-Radtke, MD,...
11/16/2023
Oncology
Sara Lonardi, MD, Veneto Institute of Oncology
Videos
Using Liquid Biopsy to Guide Post-Surgical Treatment Among Patients With Colon Cancer
11/16/2023

Featuring Sara Lonardi, MD

Featuring Sara Lonardi, MD
Sara Lonardi, MD, shares results from the PEGASUS trial which found post-surgical liquid biopsy may be used to guide the clinical management of patients with high-risk stage II or stage III colon cancer.
Sara Lonardi, MD, shares results from the PEGASUS trial which found post-surgical liquid biopsy may be used to guide the clinical management of patients with high-risk stage II or stage III colon cancer.
Sara Lonardi, MD, shares results...
11/16/2023
Oncology
Kohei Shitara, MD, PhD, National Cancer Center Hospital East
Videos
Perioperative Pembrolizumab Plus Chemotherapy for Resectable Gastric or Gastroesophageal Junction Cancer
11/14/2023

Featuring Kohei Shitara, MD, PhD

Featuring Kohei Shitara, MD, PhD ...
In the KEYNOTE-585 study, perioperative pembrolizumab plus chemotherapy improved the pathological complete response among patients with locally advanced, resectable gastric or gastroesophageal (G/GEJ) cancer, but not the event-free survival.
In the KEYNOTE-585 study, perioperative pembrolizumab plus chemotherapy improved the pathological complete response among patients with locally advanced, resectable gastric or gastroesophageal (G/GEJ) cancer, but not the event-free survival.
In the KEYNOTE-585 study,...
11/14/2023
Oncology
Quiz
Adjuvant Radiotherapy Following Radical Prostatectomy
11/13/2023
Allison Casey
Test your knowledge on the results from RADICALS RT trial evaluating adjuvant radiotherapy after radical prostatectomy.
Test your knowledge on the results from RADICALS RT trial evaluating adjuvant radiotherapy after radical prostatectomy.
Test your knowledge on the...
11/13/2023
Oncology
Oleg Gluz, MD
Conference Coverage
Static and Dynamic Biomarkers to Optimize Adjuvant Therapy in Luminal Early Breast Cancer
11/10/2023

Featuring Oleg Gluz, MD

Featuring Oleg Gluz, MD
Oleg Gluz, MD, Evangelical Bethesda Hospital, Breast Center Niederrhein, Mönchengladbach, Germany, discusses results from the prospective WSG-ADAPT HR+/HER- trial.
Oleg Gluz, MD, Evangelical Bethesda Hospital, Breast Center Niederrhein, Mönchengladbach, Germany, discusses results from the prospective WSG-ADAPT HR+/HER- trial.
Oleg Gluz, MD, Evangelical...
11/10/2023
Oncology
News
Adjuvant Radiotherapy Provided No Benefit Among Patients With Prostate Cancer Post-Radical Prostatectomy
11/10/2023
Allison Casey
Results from the phase 3 RADICALS-RT trial found there was no meaningful benefit derived from adjuvant radiotherapy following radical prostatectomy for patients with prostate cancer.
Results from the phase 3 RADICALS-RT trial found there was no meaningful benefit derived from adjuvant radiotherapy following radical prostatectomy for patients with prostate cancer.
Results from the phase 3...
11/10/2023
Oncology
News
Niraparib Plus Abiraterone Acetate and Prednisone for BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer
11/10/2023
Allison Casey
Niraparib plus abiraterone acetate and prednisone improved several outcomes measures, including overall survival, among patients with BRCA-mutant metastatic castration-resistant prostate cancer.
Niraparib plus abiraterone acetate and prednisone improved several outcomes measures, including overall survival, among patients with BRCA-mutant metastatic castration-resistant prostate cancer.
Niraparib plus abiraterone...
11/10/2023
Oncology
Ignace Vergote, MD, PhD
Conference Coverage
Tisotumab Vedotin Improves Survival, Response Among Patients With Recurrent or Metastatic Cervical Cancer
11/08/2023

Featuring Ignace Vergote, MD, PhD

Featuring Ignace Vergote, MD, PhD ...
Ignace Vergote, MD, PhD, discusses results from the phase 3 innovaTV 301/ENGOT-cx12/GOG-3057 trial.
Ignace Vergote, MD, PhD, discusses results from the phase 3 innovaTV 301/ENGOT-cx12/GOG-3057 trial.
Ignace Vergote, MD, PhD,...
11/08/2023
Oncology
Quiz
Ribociclib Plus a Nonsteroidal Aromatase Inhibitor for HR-Positive, HER2-Negative Early Breast Cancer
11/08/2023
Which of the following statements about the results of the NATALEE study are true.
Which of the following statements about the results of the NATALEE study are true.
Which of the following...
11/08/2023
Oncology
Berend van der Wilk, MD, Erasmus University Medical Center
Videos
Active Surveillance After Neoadjuvant Chemoradiation for Select Patients With Esophageal Cancer
11/07/2023

Featuring Berend van der Wilk, MD

Featuring Berend van der Wilk, MD ...
Berend van der Wilk, MD, shares results from a phase 3 trial comparing active surveillance with surgery following neoadjuvant chemoradiotherapy for patients with esophageal cancer.
Berend van der Wilk, MD, shares results from a phase 3 trial comparing active surveillance with surgery following neoadjuvant chemoradiotherapy for patients with esophageal cancer.
Berend van der Wilk, MD, shares...
11/07/2023
Oncology
Filippo Pietrantonio, MD, National Cancer Center Milan
Videos
Sotorasib Plus Panitumumab Improved PFS Among Patients With Chemorefractory KRAS G12C-Mutated Metastatic Colorectal Cancer
11/07/2023

Featuring Filippo Pietrantonio, MD

Featuring Filippo Pietrantonio, MD ...
Primary results from the phase 3 CodeBreaK 300 trial found that sotorasib plus panitumumab improved progression-free survival among patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer, compared with the standard of...
Primary results from the phase 3 CodeBreaK 300 trial found that sotorasib plus panitumumab improved progression-free survival among patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer, compared with the standard of...
Primary results from the phase 3...
11/07/2023
Oncology
Christian Rolfo, MD, PhD
Conference Coverage
Tissue and Liquid Biopsies Effective for Detecting MET Exon 14 Skipping Mutations in NSCLC
11/06/2023

Featuring Christian Rolfo, MD, PhD

Featuring Christian Rolfo, MD, PhD ...
Christian Rolfo, MD, PhD, Icahn School of Medicine, Mount Sinai Medical Center, New York, New York, discusses results from the phase 2 VISION trial.
Christian Rolfo, MD, PhD, Icahn School of Medicine, Mount Sinai Medical Center, New York, New York, discusses results from the phase 2 VISION trial.
Christian Rolfo, MD, PhD, Icahn...
11/06/2023
Oncology
News
Pertuzumab Biosimilar QL1209 Demonstrated Equivalent Efficacy, Safety to Reference Pertuzumab Among Patients With HER2-Positive Breast Cancer
11/06/2023
Allison Casey
According to a phase 3 study, QL1209, a pertuzumab biosimilar, was found to have comparable efficacy, safety, and immunogenicity to the reference product among patients with HER2-positive breast cancer.
According to a phase 3 study, QL1209, a pertuzumab biosimilar, was found to have comparable efficacy, safety, and immunogenicity to the reference product among patients with HER2-positive breast cancer.
According to a phase 3 study,...
11/06/2023
Oncology
News
Addition of 177Lu-PSMA-617 to Enzalutamide Improves PSA Outcomes Among Patients With Metastatic Castration-Resistant Prostate Cancer
11/06/2023
Allison Casey
A phase 2 study found that adding adaptive-dosed 177Lu-PSMA-617to enzalutamide improved several PSA-based outcomes among patients with metastatic castration-resistant prostate cancer.
A phase 2 study found that adding adaptive-dosed 177Lu-PSMA-617to enzalutamide improved several PSA-based outcomes among patients with metastatic castration-resistant prostate cancer.
A phase 2 study found that...
11/06/2023
Oncology
Conference Coverage
Addition of Atezolizumab to Chemotherapy and Maintenance Niraparib Did Not Improve PFS or ORR in Late-Relapsing, Recurrent Ovarian Cancer
11/03/2023

Stephanie Holland 

Stephanie Holland 
According to primary analysis results from the phase 3 ENGOT-Ov41/GEICO 69-O/ANITA study, the addition of atezolizumab to chemotherapy and maintenance niraparib did not significantly improve progression-free survival (PFS) or objective...
According to primary analysis results from the phase 3 ENGOT-Ov41/GEICO 69-O/ANITA study, the addition of atezolizumab to chemotherapy and maintenance niraparib did not significantly improve progression-free survival (PFS) or objective...
According to primary analysis...
11/03/2023
Oncology
Andrea Necchi, MD, San Raffaele Hospital
Videos
Intravesical Gemcitabine Delivery System, TAR-200, Shows Promise Among Patients With BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer
11/03/2023

Featuring Andrea Necchi, MD

Featuring Andrea Necchi, MD
Andrea Necchi, MD, describes the results from cohort 2 of the SunRISe-1 trial, evaluating TAR-200 monotherapy among patients with high-risk, BCG-unresponsive non–muscle-invasive bladder cancer.
Andrea Necchi, MD, describes the results from cohort 2 of the SunRISe-1 trial, evaluating TAR-200 monotherapy among patients with high-risk, BCG-unresponsive non–muscle-invasive bladder cancer.
Andrea Necchi, MD, describes the...
11/03/2023
Oncology
Mary McCormack, MD
Videos
Addition of Induction Chemotherapy to Standard-of-Care Chemoradiation Improves Survival Outcomes in Locally Advanced Cervical Cancer
11/02/2023

Featuring Mary McCormack, MD

Featuring Mary McCormack, MD
Mary McCormack, MD discusses results from the phase 3 GCIG INTERLACE study evaluating the addition of induction chemotherapy to standard-of-care chemoradiation among patients with advanced cervical cancer.
Mary McCormack, MD discusses results from the phase 3 GCIG INTERLACE study evaluating the addition of induction chemotherapy to standard-of-care chemoradiation among patients with advanced cervical cancer.
Mary McCormack, MD discusses...
11/02/2023
Oncology
Shahneen Sandhu, MBBS, Peter MacCallum Cancer Centre
Videos
Prevalence of DNA Repair Defects Among Patients With Metastatic Prostate Cancer
11/02/2023

Featuring Shahneen Sandhu, MBBS

Featuring Shahneen Sandhu, MBBS ...
In a prospective observational study, approximately 14% of patients with metastatic prostate cancer harbored at least 1 HRR gene alteration, most commonly BRCA.
In a prospective observational study, approximately 14% of patients with metastatic prostate cancer harbored at least 1 HRR gene alteration, most commonly BRCA.
In a prospective observational...
11/02/2023
Oncology
Conference Coverage
Neoadjuvant/Adjuvant Pembrolizumab For Patients With Resectable, Stage IIIB-IV Melanoma
11/02/2023

Stephanie Holland 

Stephanie Holland 
According to pathologic response and exploratory analyses from the SWOG S1801 study, treatment with neo/adjuvant pembrolizumab demonstrated promising response rates among patients with advanced, resectable melanoma.
According to pathologic response and exploratory analyses from the SWOG S1801 study, treatment with neo/adjuvant pembrolizumab demonstrated promising response rates among patients with advanced, resectable melanoma.
According to pathologic response...
11/02/2023
Oncology
News
Omitting Frontline Chemotherapy Lowers Toxicity Without Sacrificing Survival in Oligometastatic Head and Neck Cancer
11/02/2023

Janelle Bradley

Janelle Bradley
For patients with oligometastatic head and neck cancer, the omission of chemotherapy in the frontline setting resulted in lower toxicity rates while maintaining survival rates and quality of life, according to a phase 2 study.
For patients with oligometastatic head and neck cancer, the omission of chemotherapy in the frontline setting resulted in lower toxicity rates while maintaining survival rates and quality of life, according to a phase 2 study.
For patients with...
11/02/2023
Oncology
Aditya Bardia, MD
Videos
Addition of Ribociclib to Nonsteroidal Aromatase Inhibitor Benefits Broad Range of Patients With HR-Positive, HER2-Negative Early Breast Cancer
11/02/2023

Featuring Aditya Bardia, MD 

Featuring Aditya Bardia, MD 
Aditya Bardia, MD, discusses results from a subgroup analysis of the phase 3 NATALEE study comparing invasive disease-free survival (iDFS) across a broad range of patients with HR-positive, HER2-negative early breast cancer treated with...
Aditya Bardia, MD, discusses results from a subgroup analysis of the phase 3 NATALEE study comparing invasive disease-free survival (iDFS) across a broad range of patients with HR-positive, HER2-negative early breast cancer treated with...
Aditya Bardia, MD, discusses...
11/02/2023
Oncology
Elena Castro, MD, PhD Hospital Universitario 12 de Octubre
Videos
Niraparib Plus Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer With HRR Gene Alterations
11/01/2023

Featuring Elena Castro, MD, PhD

Featuring Elena Castro, MD, PhD ...
Elena Castro, MD, shares final results from the MAGNITUDE study evaluating niraparib plus abiraterone acetate plus prednisone for patients with metastatic castration-resistant prostate cancer and HRR gene alterations.
Elena Castro, MD, shares final results from the MAGNITUDE study evaluating niraparib plus abiraterone acetate plus prednisone for patients with metastatic castration-resistant prostate cancer and HRR gene alterations.
Elena Castro, MD, shares final...
11/01/2023
Oncology
Antoni Vilaseca, MD, Hospital Clínic de Barcelona
Videos
Novel Erdafitinib Intravesical Delivery System Showed Safety, Efficacy for Patients With Non–Muscle-Invasive Bladder Cancer With Select FGFR Alterations
11/01/2023

Featuring Antoni Vilaseca, MD

Featuring Antoni Vilaseca, MD
Antoni Vilaseca, MD, discusses the novel erdafinitib delivery system for patients with non–muscle-invasive bladder cancer (NMIBC) with select FGFR alterations.
Antoni Vilaseca, MD, discusses the novel erdafinitib delivery system for patients with non–muscle-invasive bladder cancer (NMIBC) with select FGFR alterations.
Antoni Vilaseca, MD, discusses...
11/01/2023
Oncology
News
Tipifarnib for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma With HRAS Mutations
10/31/2023

Stephanie Holland 

Stephanie Holland 
According to results from AIN-HN study, tipifarnib is safe, tolerable, and demonstrated anti-tumor activity n later-line settings among patients with HRAS-mutated recurrent or metastatic head and neck squamous cell carcinoma who had received...
According to results from AIN-HN study, tipifarnib is safe, tolerable, and demonstrated anti-tumor activity n later-line settings among patients with HRAS-mutated recurrent or metastatic head and neck squamous cell carcinoma who had received...
According to results from AIN-HN...
10/31/2023
Oncology
Conference Coverage
Standard of Care Superior to Olaparib With or Without Cediranib Among Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
10/26/2023

Stephanie Holland 

Stephanie Holland 
According to data from the phase 3 NRG-GY004 trial, olaparib with or without cediranib did not improve overall survival when compared with standard of care for patients with platinum-sensitive, relapsed ovarian cancer.
According to data from the phase 3 NRG-GY004 trial, olaparib with or without cediranib did not improve overall survival when compared with standard of care for patients with platinum-sensitive, relapsed ovarian cancer.
According to data from the phase...
10/26/2023
Oncology
Henrik Grönberg, MD, PhD, Karolinska Institute
Videos
Comparing Androgen Receptor Pathway Inhibitors and Taxanes for Metastatic Castration-Resistant Prostate Cancer in a Biomarker-Driven, Outcome-Adaptive Platform Trial
10/26/2023

Featuring Henrik Grönberg, MD, PhD

Featuring Henrik Grönberg, MD, PhD ...
Henrik Grönberg, MD, PhD, shared results from the phase 3 ProBio trial which found that androgen receptor pathway inhibitors improved survival outcomes compared to both standard of care and taxanes among patients with metastatic...
Henrik Grönberg, MD, PhD, shared results from the phase 3 ProBio trial which found that androgen receptor pathway inhibitors improved survival outcomes compared to both standard of care and taxanes among patients with metastatic...
Henrik Grönberg, MD, PhD, shared...
10/26/2023
Oncology
Aditya Bardia, MD
Conference Coverage
Datopotamab Deruxtecan for Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer
10/25/2023

Featuring Aditya Bardia, MD

Featuring Aditya Bardia, MD
Aditya Bardia, MD, discusses results from the TROPION-Breast01 trial comparing datopotamab deruxtecan with chemotherapy for patients with inoperable or metastatic hormone receptor-positive, HER2-negative breast cancer who have previously...
Aditya Bardia, MD, discusses results from the TROPION-Breast01 trial comparing datopotamab deruxtecan with chemotherapy for patients with inoperable or metastatic hormone receptor-positive, HER2-negative breast cancer who have previously...
Aditya Bardia, MD, discusses...
10/25/2023
Oncology
Oliver Sartor, MD, Mayo Clinic
Videos
177Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
10/25/2023

Featuring Oliver Sartor, MD

Featuring Oliver Sartor, MD
At the 2023 ESMO Congress, Oliver Sartor, MD, described results from the phase 3 PSMAfore trial evaluating 177Lu-PSMA-617 vs androgen receptor-directed therapy for taxane-naive patients with metastatic castration-resistant prostate cancer.
At the 2023 ESMO Congress, Oliver Sartor, MD, described results from the phase 3 PSMAfore trial evaluating 177Lu-PSMA-617 vs androgen receptor-directed therapy for taxane-naive patients with metastatic castration-resistant prostate cancer.
At the 2023 ESMO Congress,...
10/25/2023
Oncology
Conference Coverage
Maintenance Senaparib Improved PFS Among Patients With Newly Diagnosed, Advanced Ovarian Cancer
10/25/2023

Stephanie Holland 

Stephanie Holland 
According to results from the phase 3 FLAMES study, maintenance senaparib in the first-line setting significantly reduced the risk of progression or death among patients with newly diagnosed, stage 3 to 4 high-grade serous or endometrioid...
According to results from the phase 3 FLAMES study, maintenance senaparib in the first-line setting significantly reduced the risk of progression or death among patients with newly diagnosed, stage 3 to 4 high-grade serous or endometrioid...
According to results from the...
10/25/2023
Oncology
Nicolas Girard, MD, Institut Curie
Videos
PAPILLON Trial Establishes Amivantamab Plus Chemotherapy as New First-Line Standard of Care in EGFR Exon 20 Insertion-Mutated Advanced NSCLC
10/23/2023

Featuring Nicolas Girard, MD

Featuring Nicolas Girard, MD
Prof Nicolas Girard, MD, discusses primary results from the phase 3 PAPILLON study comparing amivantamab plus chemotherapy vs chemotherapy alone for the first-line treatment of patients with EGFR exon 20 insertion-mutated advanced NSCLC.
Prof Nicolas Girard, MD, discusses primary results from the phase 3 PAPILLON study comparing amivantamab plus chemotherapy vs chemotherapy alone for the first-line treatment of patients with EGFR exon 20 insertion-mutated advanced NSCLC.
Prof Nicolas Girard, MD,...
10/23/2023
Oncology
Tina Cascone, MD, PhD, MD Anderson Cancer Center
Videos
Neoadjuvant Nivolumab Plus Chemotherapy Followed By Surgery and Adjuvant Nivolumab Improves EFS in NSCLC
10/23/2023

Featuring Tina Cascone, MD, PhD

Featuring Tina Cascone, MD, PhD ...
Tina Cascone, MD, PhD, discusses results from the phase 3 CheckMate 77T trial evaluating neoadjuvant nivolumab plus chemotherapy vs placebo plus chemotherapy followed by surgery and adjuvant nivolumab vs placebo for previously untreated,...
Tina Cascone, MD, PhD, discusses results from the phase 3 CheckMate 77T trial evaluating neoadjuvant nivolumab plus chemotherapy vs placebo plus chemotherapy followed by surgery and adjuvant nivolumab vs placebo for previously untreated,...
Tina Cascone, MD, PhD, discusses...
10/23/2023
Oncology
James Catto, MBChB, PhD, FRCS, University of Sheffield
Videos
Erdafitinib vs Intravesical Chemotherapy for High-Risk Non–Muscle-Invasive Bladder Cancer
10/23/2023

Featuring James Catto, MBChB, PhD, FRCS

Featuring James Catto, MBChB, PhD, FR...
Prof James Catto, MBChB, PhD, FRCS, discusses the first randomized data from Cohort 1 of the THOR-2 trial investigating erdafitinib vs intravesical chemotherapy in high-risk FGFR-altered non–muscle-invasive bladder cancer whose disease...
Prof James Catto, MBChB, PhD, FRCS, discusses the first randomized data from Cohort 1 of the THOR-2 trial investigating erdafitinib vs intravesical chemotherapy in high-risk FGFR-altered non–muscle-invasive bladder cancer whose disease...
Prof James Catto, MBChB, PhD,...
10/23/2023
Oncology
Sherene Loi, MBBS, PhD, Peter MacCallum Cancer Center
Videos
Adding Nivolumab to Neoadjuvant Chemotherapy Improved Response Rate Among Patients With High Risk, ER Positive, HER2 Negative Breast Cancer
10/21/2023

Featuring Sherene Loi, MBBS, PhD

Featuring Sherene Loi, MBBS, PhD ...
At the 2023 ESMO Annual Congress, Sherene Loi shares results from the CheckMate 7FL trial evaluating nivolumab vs placebo plus neoadjuvant chemotherapy among patients with high-risk, ER-positive/HER2-negative breast cancer.
At the 2023 ESMO Annual Congress, Sherene Loi shares results from the CheckMate 7FL trial evaluating nivolumab vs placebo plus neoadjuvant chemotherapy among patients with high-risk, ER-positive/HER2-negative breast cancer.
At the 2023 ESMO Annual...
10/21/2023
Oncology
News
Prolonged Survival with Cancer Vaccine Among Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
10/21/2023
Allison Casey
According to a phase 2b trial, the cancer vaccine MVX-ONCO-1 demonstrated a tolerable safety profile and clinically meaningful prolonged overall survival among patients with recurrent or metastatic head and neck squamous cell carcinoma.
According to a phase 2b trial, the cancer vaccine MVX-ONCO-1 demonstrated a tolerable safety profile and clinically meaningful prolonged overall survival among patients with recurrent or metastatic head and neck squamous cell carcinoma.
According to a phase 2b trial,...
10/21/2023
Oncology
News
Efficacy, Safety of Sacituzumab Govitecan Among Patients With Heavily Pretreated, Relapsed/Refractory Metastatic or Locally Advanced Head and Neck Squamous Cell Carcinoma
10/21/2023

Stephanie Holland

Stephanie Holland
According to results from the phase 2 TROPiCS-03 study, sacituzumab govitecan demonstrated efficacy and tolerable safety among patients with heavily pretreated, relapsed or refractory, metastatic or locally advanced head and neck squamous...
According to results from the phase 2 TROPiCS-03 study, sacituzumab govitecan demonstrated efficacy and tolerable safety among patients with heavily pretreated, relapsed or refractory, metastatic or locally advanced head and neck squamous...
According to results from the...
10/21/2023
Oncology
Conference Coverage
Avelumab Plus Cetuximab Exhibits High Clinical Activity, Tolerable Safety in Advanced Cutaneous Squamous Cell Carcinoma
10/17/2023

Stephanie Holland 

Stephanie Holland 
Avelumab plus cetuximab exhibited high clinical activity and tolerable safety among patients with advanced, unresectable cutaneous squamous cell carcinoma, according to preliminary findings from the phase 2 AliCe study.
Avelumab plus cetuximab exhibited high clinical activity and tolerable safety among patients with advanced, unresectable cutaneous squamous cell carcinoma, according to preliminary findings from the phase 2 AliCe study.
Avelumab plus cetuximab...
10/17/2023
Oncology
Jean-Pascal Machiels, MD, Cliniques Universitaires Saint Luc
Videos
Pembrolizumab Added to Chemoradiotherapy May Improve EFS in Head and Neck Squamous Cell Carcinoma
11/15/2022
Jean-Pascal Machiels, MD, discusses results from the phase 3 KEYNOTE-412 trial showing the addition of pembrolizumab to chemoradiotherapy is associated with a favorable trend toward improved EFS for patients with locally advanced head and...
Jean-Pascal Machiels, MD, discusses results from the phase 3 KEYNOTE-412 trial showing the addition of pembrolizumab to chemoradiotherapy is associated with a favorable trend toward improved EFS for patients with locally advanced head and...
Jean-Pascal Machiels, MD,...
11/15/2022
Oncology
Alvaro Arjona-Sanchez, MD, Hospital Universitario Reina Sofia
Videos
Adjuvant HIPEC Before Resection Improves Locoregional Control in Patients With Locally Advanced Colon Cancer
11/14/2022
Alvaro Arjona-Sanchez, MD, explains findings from a phase 3 studyshowing HIPEC combined with mitomycin C, administered prior to surgical resection for locally advanced colon cancer, led to an improvement in locoregional control rate.
Alvaro Arjona-Sanchez, MD, explains findings from a phase 3 studyshowing HIPEC combined with mitomycin C, administered prior to surgical resection for locally advanced colon cancer, led to an improvement in locoregional control rate.
Alvaro Arjona-Sanchez, MD,...
11/14/2022
Oncology
Melissa Johnson, MD, Tennessee Oncology
Videos
Tremelimumab Added to Durvalumab and Chemotherapy Demonstrates Long-Term OS Benefit in Metastatic NSCLC
11/11/2022
Melissa Johnson, MD, discusses an OS update from the POSEIDON trial after a median follow-up of approximately 4 years, showing a durable long-term OS benefit by adding tremelimumab to durvalumab and chemotherapy for patients with metastatic...
Melissa Johnson, MD, discusses an OS update from the POSEIDON trial after a median follow-up of approximately 4 years, showing a durable long-term OS benefit by adding tremelimumab to durvalumab and chemotherapy for patients with metastatic...
Melissa Johnson, MD, discusses...
11/11/2022
Oncology
Michel Ducreux, MD, Gustave Roussy Cancer Center
Videos
FOLFIRINOX Prolongs PFS vs Gemcitabine for Patients With Unresectable Pancreatic Cancer
11/10/2022
Michel Ducreux, MD, reports results from a phase 3 trial showing FOLFIRINOX chemotherapy yields a significantly longer PFS vs gemcitabine for patients with locally advanced, unresectable pancreatic cancer.
Michel Ducreux, MD, reports results from a phase 3 trial showing FOLFIRINOX chemotherapy yields a significantly longer PFS vs gemcitabine for patients with locally advanced, unresectable pancreatic cancer.
Michel Ducreux, MD, reports...
11/10/2022
Oncology
Stephane Oudard, MD, Hôpital Européen Georges-Pompidou
Videos
Adapted Cabazitaxel Schedule Reduces Neutropenic Complications in Elderly Patients With Metastatic Castration-Resistant Prostate Cancer
11/10/2022
Stéphane Oudard, MD, reports results from a phase 3 trial demonstrating that an adapted schedule of cabazitaxel reduces neutropenic complications seen in elderly patients with metastatic castration-resistant prostate cancer without...
Stéphane Oudard, MD, reports results from a phase 3 trial demonstrating that an adapted schedule of cabazitaxel reduces neutropenic complications seen in elderly patients with metastatic castration-resistant prostate cancer without...
Stéphane Oudard, MD, reports...
11/10/2022
Oncology
Melissa Johnson, MD, Tennessee Oncology
Videos
Sotorasib Significantly Improves PFS vs Docetaxel in Patients With KRAS G12C-Mutated NSCLC
11/10/2022
Melissa Johnson, MD, discusses results from the phase 3 CodeBreaK 200 trial comparing sotorasib vs docetaxel for patients with previously treated NSCLC with a KRAS G12C mutation.
Melissa Johnson, MD, discusses results from the phase 3 CodeBreaK 200 trial comparing sotorasib vs docetaxel for patients with previously treated NSCLC with a KRAS G12C mutation.
Melissa Johnson, MD, discusses...
11/10/2022
Oncology
Axel Bex, MD, Netherlands Cancer Institute
Videos
Adjuvant Atezolizumab vs Placebo Following Nephrectomy for Patients With Renal Cell Carcinoma at Increased Risk of Recurrence
10/19/2022
Axel Bex, MD, reviews results from the phase 3 IMmotion010 trial showing no benefit to clinical outcomes with adjuvant atezolizumab vs placebo following nephrectomy for patients with renal cell carcinoma and an increased risk of recurrence.
Axel Bex, MD, reviews results from the phase 3 IMmotion010 trial showing no benefit to clinical outcomes with adjuvant atezolizumab vs placebo following nephrectomy for patients with renal cell carcinoma and an increased risk of recurrence.
Axel Bex, MD, reviews results...
10/19/2022
Oncology
Fred Saad, MD, University of Montréal Hospital Center
Videos
Olaparib Prolongs Radiographic PFS vs Placebo in Metastatic Castration-Resistant Prostate Cancer Across Subgroups
10/18/2022
Fred Saad, MD, discusses findings from a biomarker analysis of the phase 3 PROpel trial investigating abiraterone plus olaparib vs abiraterone plus placebo for patients with metastatic castration-resistant prostate cancer.
Fred Saad, MD, discusses findings from a biomarker analysis of the phase 3 PROpel trial investigating abiraterone plus olaparib vs abiraterone plus placebo for patients with metastatic castration-resistant prostate cancer.
Fred Saad, MD, discusses...
10/18/2022
Oncology
Paolo Ascierto, MD, National Cancer Institute, Naples, Italy
Videos
What is the Best Sequencing of Targeted Therapy and Immunotherapy for Metastatic BRAFV600-Mutated Melanoma?
10/18/2022
Paolo Ascierto, MD, reviews 4-year data and a preliminary biomarker analysis from a phase 2 trial exploring the ideal sequential strategy of targeted therapy and immunotherapy for patients with untreated, metastatic BRAFV60-mutated melanoma.
Paolo Ascierto, MD, reviews 4-year data and a preliminary biomarker analysis from a phase 2 trial exploring the ideal sequential strategy of targeted therapy and immunotherapy for patients with untreated, metastatic BRAFV60-mutated melanoma.
Paolo Ascierto, MD, reviews...
10/18/2022
Oncology
Sungjune Kim, MD, Moffitt Cancer Center
Videos
Nivolumab Plus Ipilimumab in the First-Line and Salvage Settings for Advanced Merkel Cell Carcinoma
10/18/2022
Sungjune Kim, MD, PhD, shares insights from a randomized phase 2 trial exploring first-line combination therapy with nivolumab and ipilimumab for patients with advanced Merkel cell carcinoma, first presented at the 2022 ESMO Congress.
Sungjune Kim, MD, PhD, shares insights from a randomized phase 2 trial exploring first-line combination therapy with nivolumab and ipilimumab for patients with advanced Merkel cell carcinoma, first presented at the 2022 ESMO Congress.
Sungjune Kim, MD, PhD, shares...
10/18/2022
Oncology
Arvind Dasari, MD, MD Anderson Cancer Center
Videos
Fruquintinib Improves Survival for Patients With Heavily Pretreated Metastatic Colorectal Cancer
09/29/2022
Arvind Dasari, MD, discusses results from phase 3 FRESNO-2 trial which demonstrated a significant survival benefit with fruquintinib for patients with highly refractory metastatic colorectal cancer.
Arvind Dasari, MD, discusses results from phase 3 FRESNO-2 trial which demonstrated a significant survival benefit with fruquintinib for patients with highly refractory metastatic colorectal cancer.
Arvind Dasari, MD, discusses...
09/29/2022
Oncology
Evan Yu, MD, Fred Hutchinson Cancer Center
Videos
Pembrolizumab Plus Olaparib Conveyed No Survival Benefit in Metastatic Castration-Resistant Prostate Cancer
09/29/2022
Evan Yu, MD, reviews the results from a phase 3 trial examining pembrolizumab plus olaparib in patients with heavily pretreated castration-resistant prostate cancer, demonstrating no improvement in survival compared to abiraterone or...
Evan Yu, MD, reviews the results from a phase 3 trial examining pembrolizumab plus olaparib in patients with heavily pretreated castration-resistant prostate cancer, demonstrating no improvement in survival compared to abiraterone or...
Evan Yu, MD, reviews the results...
09/29/2022
Oncology
Quiz
Enfortumab Vedotin Plus Pembrolizumab for Urothelial Cancer
09/27/2022
In an analysis of Cohort K from the EV-103 trial evaluating enfortumab vedotin plus pembrolizumab for cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer, did that the combination therapy have an objective...
In an analysis of Cohort K from the EV-103 trial evaluating enfortumab vedotin plus pembrolizumab for cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer, did that the combination therapy have an objective...
In an analysis of Cohort K from...
09/27/2022
Oncology
David Tougeron, MD, Poitiers University Hospital
Videos
Second-Line FOLFIRI Plus Immune Checkpoint Inhibitors Yields No Survival Benefit in Advanced Gastric or GEJ Cancers
09/20/2022
David Tougeron, MD, reviews results from the PRODIGE 59-DURIGAST trial evaluating FOLFIRI plus durvalumab and FOLFIRI plus durvalumab plus tremelimumab as a second-line treatment for patients with advanced gastric or GEJ cancer.
David Tougeron, MD, reviews results from the PRODIGE 59-DURIGAST trial evaluating FOLFIRI plus durvalumab and FOLFIRI plus durvalumab plus tremelimumab as a second-line treatment for patients with advanced gastric or GEJ cancer.
David Tougeron, MD, reviews...
09/20/2022
Oncology
Jonathan Rosenberg, MD, Memorial Sloan Kettering Cancer Center
VIDEOS
Enfortumab Vedotin Plus Pembrolizumab Induces High Response Rates in Cisplatin-Ineligible Patients With Urothelial Cancer
09/20/2022
Allison Casey
Jonathan Rosenberg, MD, reviews findings from a cohort study evaluating enfortumab vedotin monotherapy or enfortumab vedotin in combination with pembrolizumab for cisplatin-ineligible patients with urothelial cancer.
Jonathan Rosenberg, MD, reviews findings from a cohort study evaluating enfortumab vedotin monotherapy or enfortumab vedotin in combination with pembrolizumab for cisplatin-ineligible patients with urothelial cancer.
Jonathan Rosenberg, MD, reviews...
09/20/2022
Oncology
Matthew Goetz, MD, Mayo Clinic
VIDEOS
Lasofoxifene vs Fulvestrant for ESR1-Mutated Metastatic Breast Cancer With Progression on CDK4/6 Inhibitors
09/15/2022
Matthew Goetz, MD, highlights findings from the ELAINE 1 trial exploring lasofoxifene vs fulvestrant for patients with ESR1-mutated locally advanced or metastatic breast cancer who progressed on aromatase and CDK4/6 inhibitors.
Matthew Goetz, MD, highlights findings from the ELAINE 1 trial exploring lasofoxifene vs fulvestrant for patients with ESR1-mutated locally advanced or metastatic breast cancer who progressed on aromatase and CDK4/6 inhibitors.
Matthew Goetz, MD, highlights...
09/15/2022
Oncology
Keiichi Fujiwara, MD, PhD, Saitama Medical University International Medical Center
Videos
Maintenance Chemotherapy With Tegafur-Uracil vs Observation for Locally Advanced Cervical Cancer
09/15/2022
Keiichi Fujiwara, MD, PhD, discusses findings from a phase 3 trial that evaluated maintenance chemotherapy with tegafur-uracil compared to observation following concurrent chemoradiotherapy in patients with locally advanced cervical cancer.
Keiichi Fujiwara, MD, PhD, discusses findings from a phase 3 trial that evaluated maintenance chemotherapy with tegafur-uracil compared to observation following concurrent chemoradiotherapy in patients with locally advanced cervical cancer.
Keiichi Fujiwara, MD, PhD,...
09/15/2022
Oncology
Conference Coverage
Tucatinib Monotherapy and Tucatinib Plus Trastuzumab for Patients With HER2-Positive Metastatic Colorectal Cancer
09/15/2022
Allison Casey
Additional analyses from the phase 2 MOUNTAINEER study show that tucatinib monotherapy and tucatinib plus trastuzumab were well-tolerated following crossover among patients with HER2-positive colorectal cancer and the concurrent initiation of...
Additional analyses from the phase 2 MOUNTAINEER study show that tucatinib monotherapy and tucatinib plus trastuzumab were well-tolerated following crossover among patients with HER2-positive colorectal cancer and the concurrent initiation of...
Additional analyses from the...
09/15/2022
Oncology
Matthew Goetz, MD, Mayo Clinic
VIDEOS
Abemaciclib Added to a Nonsteroidal Aromatase Inhibitor Improves OS in HR-Positive, HER2-Negative Breast Cancer
09/14/2022
Matthew Goetz, MD, discusses a second interim analysis on OS results for the MONARCH 3 trial, demonstrating prolonged OS with the addition of abemaciclib to a nonsteroidal aromatase inhibitor in patients with HR-positive, HER2-negative...
Matthew Goetz, MD, discusses a second interim analysis on OS results for the MONARCH 3 trial, demonstrating prolonged OS with the addition of abemaciclib to a nonsteroidal aromatase inhibitor in patients with HR-positive, HER2-negative...
Matthew Goetz, MD, discusses a...
09/14/2022
Oncology
Bernd Kasper, MD, PhD, Mannheim Cancer Center
Videos
Nirogacestat Demonstrates Potential as Standard of Care for Progressing Desmoid Tumors Requiring Systemic Therapy
09/13/2022
Bernd Kasper, MD, PhD, discusses findings from the phase 3 DeFi trial, in which nirogacestat demonstrated a 71% reduction in the risk of disease progression or death vs placebo in patients with progressing desmoid tumors.
Bernd Kasper, MD, PhD, discusses findings from the phase 3 DeFi trial, in which nirogacestat demonstrated a 71% reduction in the risk of disease progression or death vs placebo in patients with progressing desmoid tumors.
Bernd Kasper, MD, PhD, discusses...
09/13/2022
Oncology
Sara Tolaney, MD, Dana-Farber Cancer Institute
VIDEOS
Amcenestrant vs Physician’s Choice of Endocrine Therapy in ER-Positive, HER2-Negative Breast Cancer
09/13/2022
Sara Tolaney, MD, discusses results from AMEERA-3, an open-label randomized phase 2 trial that explored amcenestrant vs physician’s choice of endocrine therapy in patients with endocrine-resistant ER-positive, HER2-negative advanced breast...
Sara Tolaney, MD, discusses results from AMEERA-3, an open-label randomized phase 2 trial that explored amcenestrant vs physician’s choice of endocrine therapy in patients with endocrine-resistant ER-positive, HER2-negative advanced breast...
Sara Tolaney, MD, discusses...
09/13/2022
Oncology
Denis Soulières, Centre Hospitalier de l’Université de Montréal
Videos
Pembrolizumab for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
09/12/2022
Denis Soulières, MD, discusses long-term follow-up data from the phase 3 KEYNOTE-040 and KEYNOTE-048 clinical trials examining pembrolizumab for patients with head and neck squamous cell carcinoma.
Denis Soulières, MD, discusses long-term follow-up data from the phase 3 KEYNOTE-040 and KEYNOTE-048 clinical trials examining pembrolizumab for patients with head and neck squamous cell carcinoma.
Denis Soulières, MD, discusses...
09/12/2022
Oncology
Conference Coverage
First-Line Atezolizumab Improved Survival Compared to Chemotherapy for Patients With NSCLC
09/12/2022
Allison Casey
According to phase 3 trial results presented at the 2022 ESMO Congress, atezolizumab in the first line improved survival outcomes for platinum-ineligible patients with NSCLC, compared to chemotherapy.
According to phase 3 trial results presented at the 2022 ESMO Congress, atezolizumab in the first line improved survival outcomes for platinum-ineligible patients with NSCLC, compared to chemotherapy.
According to phase 3 trial...
09/12/2022
Oncology
Conference Coverage
Novel Liposome Formulation of Irinotecan Plus Chemotherapy Improved Survival Outcomes for Locally Advanced and Metastatic Pancreatic Cancer
09/11/2022
Allison Casey
According to data presented at the 2022 ESMO Congress, the novel liposome formulation of irinotecan, HR070803, plus 5-FU/LV improved the survival outcomes in patients with locally advanced and metastatic pancreatic cancer when compared to...
According to data presented at the 2022 ESMO Congress, the novel liposome formulation of irinotecan, HR070803, plus 5-FU/LV improved the survival outcomes in patients with locally advanced and metastatic pancreatic cancer when compared to...
According to data presented at...
09/11/2022
Oncology
Conference Coverage
Tumor-Infiltrating Lymphocyte Therapy Improves PFS vs Ipilimumab in Advanced Melanoma
09/11/2022

Janelle Bradley

Janelle Bradley
A phase 3 study presented at the ESMO Congress found treatment with tumor-infiltrating lymphocytes significantly improves PFS vs ipilimumab in patients with advanced melanoma, including those refractory to anti-PD1 therapy.
A phase 3 study presented at the ESMO Congress found treatment with tumor-infiltrating lymphocytes significantly improves PFS vs ipilimumab in patients with advanced melanoma, including those refractory to anti-PD1 therapy.
A phase 3 study presented at the...
09/11/2022
Oncology
Conference Coverage
Dose-Dense Adjuvant Chemotherapy Yields Improved DFS, OS to Standard Schedule in Patients with Early-Stage Breast Cancer
09/10/2022
Allison Casey
Dose-dense adjuvant chemotherapy improved disease-free survival and overall survival when compared to the standard schedule for patients with node-positive breast cancer, according to data from a phase 3 trial presented at the 2022 ESMO...
Dose-dense adjuvant chemotherapy improved disease-free survival and overall survival when compared to the standard schedule for patients with node-positive breast cancer, according to data from a phase 3 trial presented at the 2022 ESMO...
Dose-dense adjuvant chemotherapy...
09/10/2022
Oncology
Conference Coverage
Perioperative Nivolumab Shows No Benefit to Recurrence-Free Survival for Patients With Renal Cell Carcinoma
09/10/2022
Allison Casey
Perioperative nivolumab did not improve recurrence-free survival for patients with renal cell carcinoma at high risk for recurrence, according to phase 3 study results presented at the 2022 ESMO Congress.
Perioperative nivolumab did not improve recurrence-free survival for patients with renal cell carcinoma at high risk for recurrence, according to phase 3 study results presented at the 2022 ESMO Congress.
Perioperative nivolumab did not...
09/10/2022
Oncology
Conference Coverage
Dalpiciclib Added to First-Line Letrozole or Anastrozole Significantly Prolongs PFS in HR-Positive HER2-Negative Breast Cancer
09/09/2022

Janelle Bradley

Janelle Bradley
Findings from the phase 3 DAWNA-2 trial show adding dalpiciclib to first-line letrozole or anastrozole significantly prolongs PFS in HR-positive, HER2-negative advanced breast cancer.
Findings from the phase 3 DAWNA-2 trial show adding dalpiciclib to first-line letrozole or anastrozole significantly prolongs PFS in HR-positive, HER2-negative advanced breast cancer.
Findings from the phase 3...
09/09/2022
Oncology
Conference Coverage
Olaparib Plus Bevacizumab Confirmed as Standard-of-Care First-Line Maintenance Regimen for Advanced Ovarian Cancer
09/09/2022
Allison Casey
In the final overall survival analysis of a phase 3 trial, olaparib plus bevacizumab was found to meaningfully improve overall survival for patients with advanced ovarian cancer and homologous recombination deficiency, with or without tumor...
In the final overall survival analysis of a phase 3 trial, olaparib plus bevacizumab was found to meaningfully improve overall survival for patients with advanced ovarian cancer and homologous recombination deficiency, with or without tumor...
In the final overall survival...
09/09/2022
Oncology
Conference Coverage
Nivolumab Plus Relatlimab Safe and Feasible for Preoperative Immune Checkpoint Inhibition in NSCLC
09/09/2022
Allison Casey
A phase 2 trial found that preoperative immune checkpoint inhibition with nivolumab plus relatlimab is both safe and feasible for patients with curatively resectable NSCLC.
A phase 2 trial found that preoperative immune checkpoint inhibition with nivolumab plus relatlimab is both safe and feasible for patients with curatively resectable NSCLC.
A phase 2 trial found that...
09/09/2022
Oncology
Conference Coverage
Atezolizumab Added to Standard Therapy in Platinum-Sensitive Ovarian Cancer
09/09/2022

Janelle Bradley

Janelle Bradley
The ATALANTE trial evaluating the addition of atezolizumab to platinum-based chemotherapy plus bevacizumab for platinum-sensitive ovarian cancer failed to meet its coprimary PFS end points, according to data presented at the 2022 ESMO...
The ATALANTE trial evaluating the addition of atezolizumab to platinum-based chemotherapy plus bevacizumab for platinum-sensitive ovarian cancer failed to meet its coprimary PFS end points, according to data presented at the 2022 ESMO...
The ATALANTE trial evaluating...
09/09/2022
Oncology
Pexidartinib Yields Tumor Regression in Patients with TGCT
11/22/2021
Pexidartinib demonstrated durable tumor regression, with manageable safety, in patients with TGCT.
Pexidartinib demonstrated durable tumor regression, with manageable safety, in patients with TGCT.
Pexidartinib demonstrated...
11/22/2021
Oncology
Dr Martinez Chanza
Videos
Avelumab-Based Neoadjuvant Chemotherapy for Patients With Non–Metastatic, Muscle-Invasive Bladder Cancer: AURA Trial
11/11/2021
Nieves Martínez Chanzá, MD, PhD, discusses the AURA trial evaluating avelumab as the basis of neoadjuvant chemotherapy in platinum-eligible and ineligible patients with non-metastatic muscle-invasive bladder cancer.
Nieves Martínez Chanzá, MD, PhD, discusses the AURA trial evaluating avelumab as the basis of neoadjuvant chemotherapy in platinum-eligible and ineligible patients with non-metastatic muscle-invasive bladder cancer.
Nieves Martínez Chanzá, MD, PhD,...
11/11/2021
Oncology
Qing Zhou, MD, PhD
Conference Insider
Lorlatinib Superior To Crizotinib in ALK+ NSCLC
10/29/2021
Results from a subgroup analyses of the CROWN trial found first-line lorlatinib offered greater PFS benefit to crizotinib in Asian patients with ALK+ NSCLC.
Results from a subgroup analyses of the CROWN trial found first-line lorlatinib offered greater PFS benefit to crizotinib in Asian patients with ALK+ NSCLC.
Results from a subgroup analyses...
10/29/2021
Oncology
Dr Powles
Videos
Dr Powles Reviews NORSE Study Results in FGFR3, FGFR2 Genetically Altered mUC
10/27/2021
Thomas Powles, MRCP, MD, discusses evaluating erdafitinib in combination with cetrelimab in patients with locally advanced or mUC with FGFR3 or FGFR2 genetic alterations ineligible for cisplatin.
Thomas Powles, MRCP, MD, discusses evaluating erdafitinib in combination with cetrelimab in patients with locally advanced or mUC with FGFR3 or FGFR2 genetic alterations ineligible for cisplatin.
Thomas Powles, MRCP, MD,...
10/27/2021
Oncology
Didier Debieuvre
Conference Coverage
Real-World Data Shows Crizotinib is Effective Treating in ALK+ and ROS1+ NSCLC
10/27/2021
French patients with advanced NSCLC with ALK-positive or ROS1-positive gene rearrangement responded well to Crizotinib, according to real-world data presented at the 2021 ESMO Congress.
French patients with advanced NSCLC with ALK-positive or ROS1-positive gene rearrangement responded well to Crizotinib, according to real-world data presented at the 2021 ESMO Congress.
French patients with advanced...
10/27/2021
Oncology
Susan Dent, MD
Videos
Dr Dent Discusses Impact of CVD and HCU in Patients With Breast Cancer
10/21/2021
Susan Dent, MD, discusses the impact of cardiovascular disease (CVD) and health care utilization (HCU) on patients with HR-positive, HER2-negative, advanced breast cancer receiving endocrine therapy.
Susan Dent, MD, discusses the impact of cardiovascular disease (CVD) and health care utilization (HCU) on patients with HR-positive, HER2-negative, advanced breast cancer receiving endocrine therapy.
Susan Dent, MD, discusses the...
10/21/2021
Oncology
Test Your Knowledge
Quiz: Which Treatment is Superior in ALK+ NSCLC?
10/15/2021
True or false: Recent data from the ESMO Congress confirm crizotinib showed greater efficacy than brigatinib for patients with ALK TKI-naïve advanced ALK+ NSCLC.
True or false: Recent data from the ESMO Congress confirm crizotinib showed greater efficacy than brigatinib for patients with ALK TKI-naïve advanced ALK+ NSCLC.
True or false: Recent data from...
10/15/2021
Oncology
Test Your Knowledge
Quiz: Which of the Following is Not a Viable TKI for ALK+ NSCLC?
10/15/2021
Multiple choice: Which of the following is not a viable TKI to use after brigatinib discontinuation for patients with ALK+ NSCLC?
Multiple choice: Which of the following is not a viable TKI to use after brigatinib discontinuation for patients with ALK+ NSCLC?
Multiple choice: Which of the...
10/15/2021
Oncology
Test Your Knowledge
Quiz: Does Vimseltinib Exhibit Antitumor Activity in TGCT?
09/30/2021
True or false: Results from a study presented at the 2021 ESMO Congress showed Vimseltinib did not yield promising antitumor activity in tenosynovial giant cell tumor (TGCT).
True or false: Results from a study presented at the 2021 ESMO Congress showed Vimseltinib did not yield promising antitumor activity in tenosynovial giant cell tumor (TGCT).
True or false: Results from a...
09/30/2021
Oncology
News
Anti-HER2 Therapy Shown to Decrease Expression in Metastatic Breast Cancer
09/29/2021
Findings were shown at the virtual 2021 ESMO Congress to support anti HER2 therapy in early metastatic breast cancer as a method to alter the molecular profile and prognosis of mBC.
Findings were shown at the virtual 2021 ESMO Congress to support anti HER2 therapy in early metastatic breast cancer as a method to alter the molecular profile and prognosis of mBC.
Findings were shown at the...
09/29/2021
Oncology
News
National Analysis Provides Greater Insights in HER2-Low Metastatic Breast Cancer
09/29/2021
Findings from a national retrospective analysis of patients with HER2-low metastatic breast cancer were presented at the virtual 2021 ESMO Congress to exhibit distinct clinical outcomes.
Findings from a national retrospective analysis of patients with HER2-low metastatic breast cancer were presented at the virtual 2021 ESMO Congress to exhibit distinct clinical outcomes.
Findings from a national...
09/29/2021
Oncology
Dr Gatti-Mays
Dr Gatti-Mays Discusses DESTINY-Breast03 Trial Results
09/29/2021
Margaret Gatti-Mays, MD, MPH, The Ohio State University, discusses the phase 2 DESTINY-Breast03 trial, data for which were presented at the 2021 ESMO Congress.
Margaret Gatti-Mays, MD, MPH, The Ohio State University, discusses the phase 2 DESTINY-Breast03 trial, data for which were presented at the 2021 ESMO Congress.
Margaret Gatti-Mays, MD, MPH,...
09/29/2021
Oncology
Saranya Chumsri, MD
Videos
Dr Chumsri Discusses Real-World Outcomes of ICIs for HR+, HER2- Metastatic Breast Cancer
09/28/2021
Saranya Chumsri, MD, Mayo Clinic, FL, highlights outcomes from a real-world study of ICIs to treat HR+, HER2-, metastatic breast cancer with a high tumor mutational burden.
Saranya Chumsri, MD, Mayo Clinic, FL, highlights outcomes from a real-world study of ICIs to treat HR+, HER2-, metastatic breast cancer with a high tumor mutational burden.
Saranya Chumsri, MD, Mayo...
09/28/2021
Oncology
Dr Punie
Clinical Videos
Kevin Punie, MD, Discusses Novel Therapy Significantly Improving QOL Over SOC in 2L+ mTNBC
09/24/2021
Dr Punie, UZ Leuven, Belgium, discusses new data from the Phase 3 ASCENT study of sacituzumab govitecan-hziy in patients with relapsed or refractory metastatic TNBC who received two or more prior systemic therapies, at least one of them for...
Dr Punie, UZ Leuven, Belgium, discusses new data from the Phase 3 ASCENT study of sacituzumab govitecan-hziy in patients with relapsed or refractory metastatic TNBC who received two or more prior systemic therapies, at least one of them for...
Dr Punie, UZ Leuven, Belgium,...
09/24/2021
Oncology
Kevin Punie, MD
Dr Punie Discusses First Treatment to Improve Survival in mTNBC
09/23/2021
Kevin Punie, MD, highlights new data from the phase 3 ASCENT study of sacituzumab govitecan-hziy, which were presented at the 2021 ESMO Congress.
Kevin Punie, MD, highlights new data from the phase 3 ASCENT study of sacituzumab govitecan-hziy, which were presented at the 2021 ESMO Congress.
Kevin Punie, MD, highlights new...
09/23/2021
Oncology
SP
Conference Coverage
Brigatinib Superior to Crizotinib in ALK NSCLC
09/22/2021
Final results from the ALTA-1L trial found that brigatinib demonstrated greater survival benefit than crizotinib in patients with ALK+ NSCLC.
Final results from the ALTA-1L trial found that brigatinib demonstrated greater survival benefit than crizotinib in patients with ALK+ NSCLC.
Final results from the ALTA-1L...
09/22/2021
Oncology
Conference Coverage
Brigatinib Yields Durable Benefit in ALK NSCLC
09/22/2021
In a recent study in ALK+ NSCLC, post-brigatinib statuses and TKI therapy was investigated to understand the clinical effects of brigatinib after treatment discontinuation.
In a recent study in ALK+ NSCLC, post-brigatinib statuses and TKI therapy was investigated to understand the clinical effects of brigatinib after treatment discontinuation.
In a recent study in ALK+ NSCLC,...
09/22/2021
Oncology
Dr Shen
Videos
Dr Shen Highlights Apalutamide Therapy for Mature Patients With Advanced Prostate Cancer
09/21/2021
John Shen, MD, UCLA, discusses a combined analysis of TITAN & SPARTAN, apalutamide (APA) therapy for older patients with advanced prostate cancer, presented at the 2021 ESMO Congress.
John Shen, MD, UCLA, discusses a combined analysis of TITAN & SPARTAN, apalutamide (APA) therapy for older patients with advanced prostate cancer, presented at the 2021 ESMO Congress.
John Shen, MD, UCLA, discusses a...
09/21/2021
Oncology
Vimseltinib Demonstrates Promising Antitumor Activity in TGCT
09/17/2021
According to data presented at the 2021 Virtual ESMO Congress, vimseltinib was well tolerated and demonstrated antitumor activity in patients with TGCT.
According to data presented at the 2021 Virtual ESMO Congress, vimseltinib was well tolerated and demonstrated antitumor activity in patients with TGCT.
According to data presented at...
09/17/2021
Oncology
Conference Coverage
Evaluating Magnitude of Clinical Benefit in the GIST, STS Treatment Landscape
09/14/2021
The ESMO-MCBS medical device was evaluated for its ability to assess the magnitude of clinical benefit, quality of life, and outcomes in advanced STS and GIST in; these data were presented at the virtual 2021 ESMO Congress.
The ESMO-MCBS medical device was evaluated for its ability to assess the magnitude of clinical benefit, quality of life, and outcomes in advanced STS and GIST in; these data were presented at the virtual 2021 ESMO Congress.
The ESMO-MCBS medical device was...
09/14/2021
Oncology
Conference Coverage
Driver Mutations Found Targetable for Wild-Type GIST
09/14/2021
Findings from a recent study were shared at the virtual 2021 ESMO Congress to present identifiable, targetable driver mutations for wild-type mutations in GIST and gain insight into developing corresponding targeted therapies.
Findings from a recent study were shared at the virtual 2021 ESMO Congress to present identifiable, targetable driver mutations for wild-type mutations in GIST and gain insight into developing corresponding targeted therapies.
Findings from a recent study...
09/14/2021
Oncology
Conference Coverage
Preliminary Data Show Ripretinib Demonstrates Efficacy in KIT-Altered Melanoma
09/14/2021
Preliminary data from an ongoing phase 1 trial of a KIT-altered melanoma cohort show that ripretinib has a manageable safety profile and demonstrates encouraging efficacy.
Preliminary data from an ongoing phase 1 trial of a KIT-altered melanoma cohort show that ripretinib has a manageable safety profile and demonstrates encouraging efficacy.
Preliminary data from an ongoing...
09/14/2021
Oncology
Conference Insider
Phase 3 INVICTUS Trial Demonstrates Ripretinib Benefit in GIST
09/14/2021
Mature data released from the phase 3 INVICTUS trial yields significantly improved PFS, reductions in disease progression, and clinically meaningful OS improvements in advanced gastrointestinal stromal tumors (GIST), presented at the virtual...
Mature data released from the phase 3 INVICTUS trial yields significantly improved PFS, reductions in disease progression, and clinically meaningful OS improvements in advanced gastrointestinal stromal tumors (GIST), presented at the virtual...
Mature data released from the...
09/14/2021
Oncology
Dr Schadendorf Discusses C.A.S.E. Study in CSCC; Current Treatment Changes
Videos
Dr Schadendorf Discusses C.A.S.E. Study in CSCC; Current Treatment Changes
10/06/2020
Dirk Schadendorf, MD, discusses demographics, prior therapies and reasons for cemiplimab treatment for CSCC, and more.
Dirk Schadendorf, MD, discusses demographics, prior therapies and reasons for cemiplimab treatment for CSCC, and more.
Dirk Schadendorf, MD, discusses...
10/06/2020
Oncology
Dr Jazieh Highlights the Prevalence of ALK+ NSCLC in the Middle East and North Africa
Podcasts
Dr Jazieh Highlights the Prevalence of ALK+ NSCLC in the Middle East and North Africa
09/28/2020
Abdul Rahman Jazieh, MD, MPH, discusses a study on the prevalence of ALK+ NSCLC in the Middle East and North Africa and the importance of testing, presented at the ESMO 2020 Virtual Congress.
Abdul Rahman Jazieh, MD, MPH, discusses a study on the prevalence of ALK+ NSCLC in the Middle East and North Africa and the importance of testing, presented at the ESMO 2020 Virtual Congress.
Abdul Rahman Jazieh, MD, MPH,...
09/28/2020
Oncology
News
Accurate Detection of PIK3CA Mutations Using ctDNA
09/25/2020
PIK3CA mutations in breast cancer can be accurately detected using ctDNA, according to analysis data presented at the ESMO 2020 Virtual Congress.
PIK3CA mutations in breast cancer can be accurately detected using ctDNA, according to analysis data presented at the ESMO 2020 Virtual Congress.
PIK3CA mutations in breast...
09/25/2020
Oncology
Conference Insider
Vemurafenib Beneficial for Nonmelanoma Cancers With BRAF V600 Mutations
09/19/2020
Study data presented by Pascale Tomasini, MD, and co-investigators at the 2020 ESMO Virtual Congress show that vemurafenib has an important role in the treatment of BRAF V600-mutated nonmelanoma cancers.
Study data presented by Pascale Tomasini, MD, and co-investigators at the 2020 ESMO Virtual Congress show that vemurafenib has an important role in the treatment of BRAF V600-mutated nonmelanoma cancers.
Study data presented by Pascale...
09/19/2020
Oncology
Autologous Hematopoietic Stem Cell Transplant Safe, Effective for HIV-Related Lymphoma
Conference Insider
Autologous Hematopoietic Stem Cell Transplant Safe, Effective for HIV-Related Lymphoma
09/19/2020
Data presented at the virtual ESMO Congress support the use of ASCT in patients with HIV-related lymphoma.
Data presented at the virtual ESMO Congress support the use of ASCT in patients with HIV-related lymphoma.
Data presented at the virtual...
09/19/2020
Oncology
Niraparib as a Standard After First-Line Chemo for Advanced Ovarian Cancer
Podcasts
Niraparib as a Standard After First-Line Chemo for Advanced Ovarian Cancer
09/19/2020
Antonio Gonzalez-Martin, MD, discusses the PRIMA study of niraparib in patients with ovarian cancer.
Antonio Gonzalez-Martin, MD, discusses the PRIMA study of niraparib in patients with ovarian cancer.
Antonio Gonzalez-Martin, MD,...
09/19/2020
Oncology
Conference Insider
Triplet Combo Regimen Yields Significant Clinical Benefit in Relapsed/Refractory MM
09/19/2020
Real-world study findings show that therapy with ixazomib plus lenalidomide and dexamethasone yields significant clinical benefits in patients with relapsed/refractory MM.
Real-world study findings show that therapy with ixazomib plus lenalidomide and dexamethasone yields significant clinical benefits in patients with relapsed/refractory MM.
Real-world study findings show...
09/19/2020
Oncology
Conference Insider
Cosibelimab Safe, Clinically Active in Patients With mCSCC
09/19/2020
Preliminary safety and efficacy data presented at ESMO 2020 Virtual Congress demonstrate that cosibelimab has a manageable safety profile and meaningful clinical activity in patients with mCSCC.
Preliminary safety and efficacy data presented at ESMO 2020 Virtual Congress demonstrate that cosibelimab has a manageable safety profile and meaningful clinical activity in patients with mCSCC.
Preliminary safety and efficacy...
09/19/2020
Oncology
Conference Insider
Neutropenia a Factor for OS in NSCLC After Gem-Carbo Therapy
09/19/2020
Among patients with NSCLC receiving gemcitabine-carboplatin chemo, neutropenia may predict OS, according to long-term follow-up data presented at the ESMO 2020 Virtual Congress.
Among patients with NSCLC receiving gemcitabine-carboplatin chemo, neutropenia may predict OS, according to long-term follow-up data presented at the ESMO 2020 Virtual Congress.
Among patients with NSCLC...
09/19/2020
Oncology
Onvansertib Combined With Standard-Care Chemo Safe, Well-Tolerated in AML
Videos
Onvansertib Combined With Standard-Care Chemo Safe, Well-Tolerated in AML
09/19/2020
Amer Zeidan, MBBS, discusses a trial exploring onvansertinib plus standard-of-care chemo in patients with AML.
Amer Zeidan, MBBS, discusses a trial exploring onvansertinib plus standard-of-care chemo in patients with AML.
Amer Zeidan, MBBS, discusses a...
09/19/2020
Oncology

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement